(function(){ var content_array=["

關于<\/b>RedHill Biopharma<\/b>     <\/b><\/p> \n

RedHill Biopharma Ltd.（納斯達克股票代碼：RDHL）是一家主要專注于胃腸道疾病和傳染病的特種生物制藥公司。RedHill推廣以下胃腸道藥物：Movantik®<\/sup><\/b>用于治療類鴉片引起的成人便秘，Talicia®<\/sup><\/b>用于治療成人幽門螺旋桿菌(H. pylori<\/i>)感染，以及Aemcolo®<\/sup><\/b>用于治療成人旅行者腹瀉。RedHill的關鍵臨床后期開發計劃包括：(i) RHB-204<\/b>，計劃進行一項針對肺部非結核分枝桿菌（NTM）疾病感染的3期研究；(ii) opaganib<\/b>（<\/b>ABC294640<\/b>）<\/b>，一種同類首創的針對多種適應癥的口服SK2選擇性抑制劑，針對新冠肺炎的全球2\/3期口服藥物項目和針對前列腺癌和膽管癌的2期研究；(iii) RHB-107<\/b> (upamostat<\/b>)，一種口服絲氨酸蛋白酶抑制劑，正在美國進行針對癥狀型新冠肺炎的2\/3期研究，并靶向多種其他癌癥和炎癥性胃腸疾病；(iv) RHB-104<\/b>，在克羅恩病的首次3期研究中獲得積極結果；(v) RHB-102<\/b>，在急性胃腸炎和胃炎的3期研究中獲得積極結果，在IBS-D的2期研究中獲得積極結果；和 (vi) RHB<\/b>-106<\/b>，一種封裝的腸制劑。公司更多相關信息請見www.redhillbio.com<\/a> \/ https:\/\/twitter.com\/RedHillBio<\/a>。<\/p> \n

注意：本新聞稿是對公司以英文發布的官方新聞稿的譯文，為方便查閱而提供。如需獲得英文版完整新聞稿，包括前瞻性聲明的免責聲明，請訪問：https:\/\/ir.redhillbio.com\/press-releases<\/a>  <\/i><\/p> \n

 <\/p> \n

\n \n \n \n

公司<\/b>聯系人：<\/b>
Adi Frish
首席企業和業務發展官

RedHill Biopharma
+972-54-6543-112
adi@redhillbio.com<\/a> <\/span><\/p> <\/td> \n

媒體<\/b>聯系人：<\/b>
<\/b>美國<\/b>：Bryan Gibbs，Finn Partners
+1 212 529 2236
bryan.gibbs@finnpartners.com
英國：<\/b>Amber Fennell，Consilium
+44 (0) 7739 658 783 
fennell@consilium-comms.com<\/a> <\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n

 <\/p> \n

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

REDHILL BIOPHARMA LTD.<\/b> <\/span><\/p> <\/td> \n <\/tr> \n

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS <\/span><\/p> <\/td> \n <\/tr> \n

(Unaudited) <\/span><\/p> <\/td> \n <\/tr> \n


<\/td> \n <\/tr> \n

<\/td> \n
<\/td> \n

Three Months Ended <\/b><\/span><\/p> <\/td> \n


<\/td> \n

Six Months Ended <\/b><\/span><\/p> <\/td> \n <\/tr> \n


<\/td> \n
<\/td> \n

June 30, <\/b> <\/span><\/p> <\/td> \n


<\/td> \n

June 30, <\/b> <\/span><\/p> <\/td> \n <\/tr> \n


<\/td> \n
<\/td> \n

2021<\/b><\/span><\/p> <\/td> \n


<\/td> \n

2020<\/b><\/span><\/p> <\/td> \n


<\/td> \n

2021<\/b><\/span><\/p> <\/td> \n


<\/td> \n

2020<\/b><\/span><\/p> <\/td> \n <\/tr> \n


<\/td> \n
<\/td> \n

U.S. dollars in thousands<\/b> <\/span><\/p> <\/td> \n <\/tr> \n

NET REVENUES<\/b> <\/span><\/p> <\/td> \n


<\/td> \n

21,502<\/span><\/p> <\/td> \n


<\/td> \n

20,899<\/span><\/p> <\/td> \n


<\/td> \n

42,077<\/span><\/p> <\/td> \n


<\/td> \n

21,955<\/span><\/p> <\/td> \n <\/tr> \n

COST OF REVENUES<\/b> <\/span><\/p> <\/td> \n


<\/td> \n

10,590<\/span><\/p> <\/td> \n


<\/td> \n

14,188<\/span><\/p> <\/td> \n


<\/td> \n

20,843<\/span><\/p> <\/td> \n


<\/td> \n

15,903<\/span><\/p> <\/td> \n <\/tr> \n

GROSS PROFIT <\/b><\/span><\/p> <\/td> \n


<\/td> \n

10,912<\/span><\/p> <\/td> \n


<\/td> \n

6,711<\/span><\/p> <\/td> \n


<\/td> \n

21,234<\/span><\/p> <\/td> \n


<\/td> \n

6,052<\/span><\/p> <\/td> \n <\/tr> \n

RESEARCH AND DEVELOPMENT EXPENSES<\/b> <\/span><\/p> <\/td> \n


<\/td> \n

10,328<\/span><\/p> <\/td> \n


<\/td> \n

3,214<\/span><\/p> <\/td> \n


<\/td> \n

17,812<\/span><\/p> <\/td> \n


<\/td> \n

5,979<\/span><\/p> <\/td> \n <\/tr> \n

SELLING AND MARKETING EXPENSES<\/b> <\/span><\/p> <\/td> \n


<\/td> \n

15,235<\/span><\/p> <\/td> \n


<\/td> \n

9,964<\/span><\/p> <\/td> \n


<\/td> \n

29,130<\/span><\/p> <\/td> \n


<\/td> \n

18,970<\/span><\/p> <\/td> \n <\/tr> \n

GENERAL AND ADMINISTRATIVE EXPENSES<\/b> <\/span><\/p> <\/td> \n


<\/td> \n

10,235<\/span><\/p> <\/td> \n


<\/td> \n

6,033<\/span><\/p> <\/td> \n


<\/td> \n

17,330<\/span><\/p> <\/td> \n


<\/td> \n

10,619<\/span><\/p> <\/td> \n <\/tr> \n

OPERATING LOSS<\/b> <\/span><\/p> <\/td> \n


<\/td> \n

24,886<\/span><\/p> <\/td> \n


<\/td> \n

12,500<\/span><\/p> <\/td> \n


<\/td> \n

43,038<\/span><\/p> <\/td> \n


<\/td> \n

29,516<\/span><\/p> <\/td> \n <\/tr> \n

FINANCIAL INCOME <\/b><\/span><\/p> <\/td> \n


<\/td> \n

15<\/span><\/p> <\/td> \n


<\/td> \n

108<\/span><\/p> <\/td> \n


<\/td> \n

31<\/span><\/p> <\/td> \n


<\/td> \n

322<\/span><\/p> <\/td> \n <\/tr> \n

FINANCIAL EXPENSES<\/b> <\/span><\/p> <\/td> \n


<\/td> \n

4,250<\/span><\/p> <\/td> \n


<\/td> \n

3,655<\/span><\/p> <\/td> \n


<\/td> \n

8,977<\/span><\/p> <\/td> \n


<\/td> \n

4,010<\/span><\/p> <\/td> \n <\/tr> \n

FINANCIAL EXPENSES, <\/b>net <\/span><\/p> <\/td> \n


<\/td> \n

4,235<\/span><\/p> <\/td> \n


<\/td> \n

3,547<\/span><\/p> <\/td> \n


<\/td> \n

8,946<\/span><\/p> <\/td> \n


<\/td> \n

3,688<\/span><\/p> <\/td> \n <\/tr> \n

LOSS AND COMPREHENSIVE LOSS FOR THE PERIOD<\/b> <\/span><\/p> <\/td> \n


<\/td> \n

29,121<\/span><\/p> <\/td> \n


<\/td> \n

16,047<\/span><\/p> <\/td> \n


<\/td> \n

51,984<\/span><\/p> <\/td> \n


<\/td> \n

33,204<\/span><\/p> <\/td> \n <\/tr> \n


<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n

LOSS PER ORDINARY SHARE, basic and diluted<\/b> (U.S. dollars):<\/b> <\/span><\/p> <\/td> \n


<\/td> \n

0.06<\/span><\/p> <\/td> \n


<\/td> \n

0.04<\/span><\/p> <\/td> \n


<\/td> \n

0.12<\/span><\/p> <\/td> \n


<\/td> \n

0.09<\/span><\/p> <\/td> \n <\/tr> \n

WEIGHTED AVERAGE OF ORDINARY SHARES<\/b> (in thousands) <\/span><\/p> <\/td> \n


<\/td> \n

466,801<\/span><\/p> <\/td> \n


<\/td> \n

357,668<\/span><\/p> <\/td> \n


<\/td> \n

448,411<\/span><\/p> <\/td> \n


<\/td> \n

355,168<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n

 <\/p> \n

 <\/p> \n

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

REDHILL BIOPHARMA LTD.<\/b> <\/span><\/p> <\/td> \n <\/tr> \n

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION <\/span><\/p> <\/td> \n <\/tr> \n


<\/td> \n <\/tr> \n

<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n

<\/td> \n
<\/td> \n

June 30, <\/b> <\/span><\/p> <\/td> \n


<\/td> \n

December 31, <\/b> <\/span><\/p> <\/td> \n <\/tr> \n


<\/td> \n
<\/td> \n

2021<\/b><\/span><\/p> <\/td> \n


<\/td> \n

2020<\/b><\/span><\/p> <\/td> \n <\/tr> \n


<\/td> \n
<\/td> \n

Unaudited  Audited<\/b> <\/span><\/p> <\/td> \n <\/tr> \n


<\/td> \n
<\/td> \n

 U.S. dollars in thousands<\/b> <\/span><\/p> <\/td> \n <\/tr> \n

CURRENT ASSETS:<\/b> <\/span><\/p> <\/td> \n


<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n

Cash and cash equivalents <\/span><\/p> <\/td> \n


<\/td> \n

51,816<\/span><\/p> <\/td> \n


<\/td> \n

29,295<\/span><\/p> <\/td> \n <\/tr> \n

Bank deposits <\/span><\/p> <\/td> \n


<\/td> \n

3,521<\/span><\/p> <\/td> \n


<\/td> \n

17<\/span><\/p> <\/td> \n <\/tr> \n

Financial assets at fair value through profit or loss <\/span><\/p> <\/td> \n


<\/td> \n

—<\/span><\/p> <\/td> \n


<\/td> \n

481<\/span><\/p> <\/td> \n <\/tr> \n

Trade receivables <\/span><\/p> <\/td> \n


<\/td> \n

30,098<\/span><\/p> <\/td> \n


<\/td> \n

28,655<\/span><\/p> <\/td> \n <\/tr> \n

Prepaid expenses and other receivables <\/span><\/p> <\/td> \n


<\/td> \n

4,292<\/span><\/p> <\/td> \n


<\/td> \n

5,521<\/span><\/p> <\/td> \n <\/tr> \n

Inventory <\/span><\/p> <\/td> \n


<\/td> \n

8,763<\/span><\/p> <\/td> \n


<\/td> \n

6,526<\/span><\/p> <\/td> \n <\/tr> \n


<\/td> \n
<\/td> \n

98,490<\/span><\/p> <\/td> \n


<\/td> \n

70,495<\/span><\/p> <\/td> \n <\/tr> \n

NON-CURRENT ASSETS:<\/b> <\/span><\/p> <\/td> \n


<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n

Restricted cash <\/span><\/p> <\/td> \n


<\/td> \n

16,161<\/span><\/p> <\/td> \n


<\/td> \n

16,164<\/span><\/p> <\/td> \n <\/tr> \n

Fixed assets <\/span><\/p> <\/td> \n


<\/td> \n

506<\/span><\/p> <\/td> \n


<\/td> \n

511<\/span><\/p> <\/td> \n <\/tr> \n

Right-of-use assets <\/span><\/p> <\/td> \n


<\/td> \n

4,294<\/span><\/p> <\/td> \n


<\/td> \n

5,192<\/span><\/p> <\/td> \n <\/tr> \n

Intangible assets <\/span><\/p> <\/td> \n


<\/td> \n

84,222<\/span><\/p> <\/td> \n


<\/td> \n

87,879<\/span><\/p> <\/td> \n <\/tr> \n


<\/td> \n
<\/td> \n

105,183<\/span><\/p> <\/td> \n


<\/td> \n

109,746<\/span><\/p> <\/td> \n <\/tr> \n

TOTAL ASSETS<\/b> <\/span><\/p> <\/td> \n


<\/td> \n

203,673<\/span><\/p> <\/td> \n


<\/td> \n

180,241<\/span><\/p> <\/td> \n <\/tr> \n


<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n

<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n

CURRENT LIABILITIES:  <\/b><\/span><\/p> <\/td> \n


<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n

Accounts payable <\/span><\/p> <\/td> \n


<\/td> \n

13,306<\/span><\/p> <\/td> \n


<\/td> \n

11,553<\/span><\/p> <\/td> \n <\/tr> \n

Lease liabilities <\/span><\/p> <\/td> \n


<\/td> \n

1,692<\/span><\/p> <\/td> \n


<\/td> \n

1,710<\/span><\/p> <\/td> \n <\/tr> \n

Allowance for deductions from revenues <\/span><\/p> <\/td> \n


<\/td> \n

26,096<\/span><\/p> <\/td> \n


<\/td> \n

18,343<\/span><\/p> <\/td> \n <\/tr> \n

Accrued expenses and other current liabilities <\/span><\/p> <\/td> \n


<\/td> \n

23,162<\/span><\/p> <\/td> \n


<\/td> \n

24,082<\/span><\/p> <\/td> \n <\/tr> \n

Payable in respect of intangible assets purchase <\/span><\/p> <\/td> \n


<\/td> \n

14,916<\/span><\/p> <\/td> \n


<\/td> \n

17,547<\/span><\/p> <\/td> \n <\/tr> \n


<\/td> \n
<\/td> \n

79,172<\/span><\/p> <\/td> \n


<\/td> \n

73,235<\/span><\/p> <\/td> \n <\/tr> \n


<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n

NON-CURRENT LIABILITIES:<\/b> <\/span><\/p> <\/td> \n


<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n

Borrowing <\/span><\/p> <\/td> \n


<\/td> \n

83,159<\/span><\/p> <\/td> \n


<\/td> \n

81,386<\/span><\/p> <\/td> \n <\/tr> \n

Payable in respect of intangible assets purchase <\/span><\/p> <\/td> \n


<\/td> \n

8,035<\/span><\/p> <\/td> \n


<\/td> \n

7,199<\/span><\/p> <\/td> \n <\/tr> \n

Lease liabilities <\/span><\/p> <\/td> \n


<\/td> \n

2,976<\/span><\/p> <\/td> \n


<\/td> \n

3,807<\/span><\/p> <\/td> \n <\/tr> \n

Royalty obligation <\/span><\/p> <\/td> \n


<\/td> \n

750<\/span><\/p> <\/td> \n


<\/td> \n

750<\/span><\/p> <\/td> \n <\/tr> \n


<\/td> \n
<\/td> \n

94,920<\/span><\/p> <\/td> \n


<\/td> \n

93,142<\/span><\/p> <\/td> \n <\/tr> \n

TOTAL LIABILITIES<\/b> <\/span><\/p> <\/td> \n


<\/td> \n

174,092<\/span><\/p> <\/td> \n


<\/td> \n

166,377<\/span><\/p> <\/td> \n <\/tr> \n


<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n

EQUITY:<\/b> <\/span><\/p> <\/td> \n


<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n

Ordinary shares <\/span><\/p> <\/td> \n


<\/td> \n

1,311<\/span><\/p> <\/td> \n


<\/td> \n

1,054<\/span><\/p> <\/td> \n <\/tr> \n

Additional paid-in capital <\/span><\/p> <\/td> \n


<\/td> \n

354,442<\/span><\/p> <\/td> \n


<\/td> \n

293,144<\/span><\/p> <\/td> \n <\/tr> \n

Accumulated deficit <\/span><\/p> <\/td> \n


<\/td> \n

(326,172)<\/span><\/p> <\/td> \n


<\/td> \n

(280,334)<\/span><\/p> <\/td> \n <\/tr> \n

TOTAL EQUITY<\/b> <\/span><\/p> <\/td> \n


<\/td> \n

29,581<\/span><\/p> <\/td> \n


<\/td> \n

13,864<\/span><\/p> <\/td> \n <\/tr> \n

TOTAL LIABILITIES AND EQUITY<\/b> <\/span><\/p> <\/td> \n


<\/td> \n

203,673<\/span><\/p> <\/td> \n


<\/td> \n

180,241<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n

 <\/p> \n

 <\/p> \n

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

REDHILL BIOPHARMA LTD.<\/b> <\/span><\/p> <\/td> \n <\/tr> \n

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS <\/span><\/p> <\/td> \n <\/tr> \n

(Unaudited) <\/span><\/p> <\/td> \n <\/tr> \n


<\/td> \n <\/tr> \n

<\/td> \n
<\/td> \n

Three Months Ended <\/b><\/span><\/p> <\/td> \n


<\/td> \n

Six Months Ended <\/b><\/span><\/p> <\/td> \n <\/tr> \n


<\/td> \n
<\/td> \n

June 30, <\/b> <\/span><\/p> <\/td> \n


<\/td> \n

June 30, <\/b> <\/span><\/p> <\/td> \n <\/tr> \n


<\/td> \n
<\/td> \n

2021<\/b><\/span><\/p> <\/td> \n


<\/td> \n

2020<\/b><\/span><\/p> <\/td> \n


<\/td> \n

2021<\/b><\/span><\/p> <\/td> \n


<\/td> \n

2020<\/b><\/span><\/p> <\/td> \n <\/tr> \n


<\/td> \n
<\/td> \n

U.S. dollars in thousands<\/b> <\/span><\/p> <\/td> \n <\/tr> \n

OPERATING ACTIVITIES:<\/b> <\/span><\/p> <\/td> \n


<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n

Comprehensive loss <\/span><\/p> <\/td> \n


<\/td> \n

(29,121)<\/span><\/p> <\/td> \n


<\/td> \n

(16,047)<\/span><\/p> <\/td> \n


<\/td> \n

(51,984)<\/span><\/p> <\/td> \n


<\/td> \n

(33,204)<\/span><\/p> <\/td> \n <\/tr> \n

Adjustments in respect of income and expenses not involving cash flow: <\/span><\/p> <\/td> \n


<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n

Share-based compensation to employees and service providers <\/span><\/p> <\/td> \n


<\/td> \n

5,274<\/span><\/p> <\/td> \n


<\/td> \n

623<\/span><\/p> <\/td> \n


<\/td> \n

6,146<\/span><\/p> <\/td> \n


<\/td> \n

1,425<\/span><\/p> <\/td> \n <\/tr> \n

Depreciation <\/span><\/p> <\/td> \n


<\/td> \n

465<\/span><\/p> <\/td> \n


<\/td> \n

417<\/span><\/p> <\/td> \n


<\/td> \n

957<\/span><\/p> <\/td> \n


<\/td> \n

767<\/span><\/p> <\/td> \n <\/tr> \n

Amortization and impairment of intangible assets <\/span><\/p> <\/td> \n


<\/td> \n

1,830<\/span><\/p> <\/td> \n


<\/td> \n

1,773<\/span><\/p> <\/td> \n


<\/td> \n

3,657<\/span><\/p> <\/td> \n


<\/td> \n

2,849<\/span><\/p> <\/td> \n <\/tr> \n

Non-cash interest expenses related to borrowing and payable in respect of intangible assets purchase <\/span><\/p> <\/td> \n


<\/td> \n

1,217<\/span><\/p> <\/td> \n


<\/td> \n

1,513<\/span><\/p> <\/td> \n


<\/td> \n

3,856<\/span><\/p> <\/td> \n


<\/td> \n

1,617<\/span><\/p> <\/td> \n <\/tr> \n

Fair value losses (gains) on financial assets at fair value through profit or loss <\/span><\/p> <\/td> \n


<\/td> \n

—<\/span><\/p> <\/td> \n


<\/td> \n

(38)<\/span><\/p> <\/td> \n


<\/td> \n

6<\/span><\/p> <\/td> \n


<\/td> \n

37<\/span><\/p> <\/td> \n <\/tr> \n

Exchange differences and revaluation of bank deposits <\/span><\/p> <\/td> \n


<\/td> \n

17<\/span><\/p> <\/td> \n


<\/td> \n

(6)<\/span><\/p> <\/td> \n


<\/td> \n

63<\/span><\/p> <\/td> \n


<\/td> \n

(165)<\/span><\/p> <\/td> \n <\/tr> \n


<\/td> \n
<\/td> \n

8,803<\/span><\/p> <\/td> \n


<\/td> \n

4,282<\/span><\/p> <\/td> \n


<\/td> \n

14,685<\/span><\/p> <\/td> \n


<\/td> \n

6,530<\/span><\/p> <\/td> \n <\/tr> \n

Changes in assets and liability items: <\/span><\/p> <\/td> \n


<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n

Increase in trade receivables <\/span><\/p> <\/td> \n


<\/td> \n

(6,792)<\/span><\/p> <\/td> \n


<\/td> \n

(16,853)<\/span><\/p> <\/td> \n


<\/td> \n

(1,443)<\/span><\/p> <\/td> \n


<\/td> \n

(17,354)<\/span><\/p> <\/td> \n <\/tr> \n

Decrease (increase) in prepaid expenses and other receivables <\/span><\/p> <\/td> \n


<\/td> \n

(199)<\/span><\/p> <\/td> \n


<\/td> \n

(3,266)<\/span><\/p> <\/td> \n


<\/td> \n

1,229<\/span><\/p> <\/td> \n


<\/td> \n

(2,626)<\/span><\/p> <\/td> \n <\/tr> \n

Decrease (increase) in inventories <\/span><\/p> <\/td> \n


<\/td> \n

507<\/span><\/p> <\/td> \n


<\/td> \n

(1,983)<\/span><\/p> <\/td> \n


<\/td> \n

(2,237)<\/span><\/p> <\/td> \n


<\/td> \n

(2,868)<\/span><\/p> <\/td> \n <\/tr> \n

Increase in accounts payable <\/span><\/p> <\/td> \n


<\/td> \n

6,770<\/span><\/p> <\/td> \n


<\/td> \n

2,123<\/span><\/p> <\/td> \n


<\/td> \n

1,753<\/span><\/p> <\/td> \n


<\/td> \n

1,124<\/span><\/p> <\/td> \n <\/tr> \n

Increase (decrease) in accrued expenses and other liabilities <\/span><\/p> <\/td> \n


<\/td> \n

(2,284)<\/span><\/p> <\/td> \n


<\/td> \n

17,804<\/span><\/p> <\/td> \n


<\/td> \n

(920)<\/span><\/p> <\/td> \n


<\/td> \n

22,123<\/span><\/p> <\/td> \n <\/tr> \n

Increase (decrease) in allowance for deductions from revenues <\/span><\/p> <\/td> \n


<\/td> \n

3,418<\/span><\/p> <\/td> \n


<\/td> \n

(1,089)<\/span><\/p> <\/td> \n


<\/td> \n

7,753<\/span><\/p> <\/td> \n


<\/td> \n

(428)<\/span><\/p> <\/td> \n <\/tr> \n


<\/td> \n
<\/td> \n

1,420<\/span><\/p> <\/td> \n


<\/td> \n

(3,264)<\/span><\/p> <\/td> \n


<\/td> \n

6,135<\/span><\/p> <\/td> \n


<\/td> \n

(29)<\/span><\/p> <\/td> \n <\/tr> \n

Net cash used in operating activities<\/b> <\/span><\/p> <\/td> \n


<\/td> \n

(18,898)<\/b><\/span><\/p> <\/td> \n


<\/td> \n

(15,029)<\/b><\/span><\/p> <\/td> \n


<\/td> \n

(31,164)<\/b><\/span><\/p> <\/td> \n


<\/td> \n

(26,703)<\/b><\/span><\/p> <\/td> \n <\/tr> \n

INVESTING ACTIVITIES: <\/b><\/span><\/p> <\/td> \n


<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n

Purchase of fixed assets <\/span><\/p> <\/td> \n


<\/td> \n

(3)<\/span><\/p> <\/td> \n


<\/td> \n

(20)<\/span><\/p> <\/td> \n


<\/td> \n

(91)<\/span><\/p> <\/td> \n


<\/td> \n

(191)<\/span><\/p> <\/td> \n <\/tr> \n

Purchase of intangible assets <\/span><\/p> <\/td> \n


<\/td> \n

—<\/span><\/p> <\/td> \n


<\/td> \n

(52,500)<\/span><\/p> <\/td> \n


<\/td> \n

—<\/span><\/p> <\/td> \n


<\/td> \n

(52,633)<\/span><\/p> <\/td> \n <\/tr> \n

Change in investment in current bank deposits <\/span><\/p> <\/td> \n


<\/td> \n

(3,500)<\/span><\/p> <\/td> \n


<\/td> \n

1,000<\/span><\/p> <\/td> \n


<\/td> \n

(3,500)<\/span><\/p> <\/td> \n


<\/td> \n

4,200<\/span><\/p> <\/td> \n <\/tr> \n

Proceeds from sale of financial assets at fair value through profit or loss <\/span><\/p> <\/td> \n


<\/td> \n

—<\/span><\/p> <\/td> \n


<\/td> \n

1,725<\/span><\/p> <\/td> \n


<\/td> \n

475<\/span><\/p> <\/td> \n


<\/td> \n

3,950<\/span><\/p> <\/td> \n <\/tr> \n

Net cash (used in) investing activities<\/b> <\/span><\/p> <\/td> \n


<\/td> \n

(3,503)<\/b><\/span><\/p> <\/td> \n


<\/td> \n

(49,795)<\/b><\/span><\/p> <\/td> \n


<\/td> \n

(3,116)<\/b><\/span><\/p> <\/td> \n


<\/td> \n

(44,674)<\/b><\/span><\/p> <\/td> \n <\/tr> \n

FINANCING ACTIVITIES:<\/b> <\/span><\/p> <\/td> \n


<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n

Proceeds from long-term borrowings, net of transaction costs <\/span><\/p> <\/td> \n


<\/td> \n

—<\/span><\/p> <\/td> \n


<\/td> \n

(500)<\/span><\/p> <\/td> \n


<\/td> \n

—<\/span><\/p> <\/td> \n


<\/td> \n

78,845<\/span><\/p> <\/td> \n <\/tr> \n

Proceeds from issuance of ordinary shares, net of issuance costs <\/span><\/p> <\/td> \n


<\/td> \n

273<\/span><\/p> <\/td> \n


<\/td> \n

6,363<\/span><\/p> <\/td> \n


<\/td> \n

58,214<\/span><\/p> <\/td> \n


<\/td> \n

6,363<\/span><\/p> <\/td> \n <\/tr> \n

Exercise of options into ordinary shares <\/span><\/p> <\/td> \n


<\/td> \n

114<\/span><\/p> <\/td> \n


<\/td> \n

—<\/span><\/p> <\/td> \n


<\/td> \n

3,341<\/span><\/p> <\/td> \n


<\/td> \n

—<\/span><\/p> <\/td> \n <\/tr> \n

Repayment of payable in respect of intangible asset purchase <\/span><\/p> <\/td> \n


<\/td> \n

(1,754)<\/span><\/p> <\/td> \n


<\/td> \n

—<\/span><\/p> <\/td> \n


<\/td> \n

(3,879)<\/span><\/p> <\/td> \n


<\/td> \n

—<\/span><\/p> <\/td> \n <\/tr> \n

Increase in restricted cash <\/span><\/p> <\/td> \n


<\/td> \n

—<\/span><\/p> <\/td> \n


<\/td> \n

—<\/span><\/p> <\/td> \n


<\/td> \n

—<\/span><\/p> <\/td> \n


<\/td> \n

(20,000)<\/span><\/p> <\/td> \n <\/tr> \n

Payment of principal with respect to lease liabilities <\/span><\/p> <\/td> \n


<\/td> \n

(402)<\/span><\/p> <\/td> \n


<\/td> \n

(404)<\/span><\/p> <\/td> \n


<\/td> \n

(785)<\/span><\/p> <\/td> \n


<\/td> \n

(736)<\/span><\/p> <\/td> \n <\/tr> \n

Net cash (used in) provided by financing activities<\/b> <\/span><\/p> <\/td> \n


<\/td> \n

(1,769)<\/b><\/span><\/p> <\/td> \n


<\/td> \n

5,459<\/b><\/span><\/p> <\/td> \n


<\/td> \n

56,891<\/b><\/span><\/p> <\/td> \n


<\/td> \n

64,472<\/b><\/span><\/p> <\/td> \n <\/tr> \n

INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS<\/b> <\/span><\/p> <\/td> \n


<\/td> \n

(24,170)<\/span><\/p> <\/td> \n


<\/td> \n

(59,365)<\/span><\/p> <\/td> \n


<\/td> \n

22,612<\/span><\/p> <\/td> \n


<\/td> \n

(6,905)<\/span><\/p> <\/td> \n <\/tr> \n

EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS<\/b> <\/span><\/p> <\/td> \n


<\/td> \n

14<\/span><\/p> <\/td> \n


<\/td> \n

23<\/span><\/p> <\/td> \n


<\/td> \n

(91)<\/span><\/p> <\/td> \n


<\/td> \n

154<\/span><\/p> <\/td> \n <\/tr> \n

BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD<\/b> <\/span><\/p> <\/td> \n


<\/td> \n

75,972<\/span><\/p> <\/td> \n


<\/td> \n

81,614<\/span><\/p> <\/td> \n


<\/td> \n

29,295<\/span><\/p> <\/td> \n


<\/td> \n

29,023<\/span><\/p> <\/td> \n <\/tr> \n

BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD<\/b> <\/span><\/p> <\/td> \n


<\/td> \n

51,816<\/span><\/p> <\/td> \n


<\/td> \n

22,272<\/span><\/p> <\/td> \n


<\/td> \n

51,816<\/span><\/p> <\/td> \n


<\/td> \n

22,272<\/span><\/p> <\/td> \n <\/tr> \n

SUPPLEMENTARY INFORMATION ON INTEREST RECEIVED IN CASH<\/b> <\/span><\/p> <\/td> \n


<\/td> \n

52<\/span><\/p> <\/td> \n


<\/td> \n

71<\/span><\/p> <\/td> \n


<\/td> \n

71<\/span><\/p> <\/td> \n


<\/td> \n

249<\/span><\/p> <\/td> \n <\/tr> \n

SUPPLEMENTARY INFORMATION ON INTEREST PAID IN CASH<\/b> <\/span><\/p> <\/td> \n


<\/td> \n

3,026<\/span><\/p> <\/td> \n


<\/td> \n

2,129<\/span><\/p> <\/td> \n


<\/td> \n

5,016<\/span><\/p> <\/td> \n


<\/td> \n

2,360<\/span><\/p> <\/td> \n <\/tr> \n

SUPPLEMENTARY INFORMATION ON NON-CASH INVESTING AND FINANCING ACTIVITIES:<\/b> <\/span><\/p> <\/td> \n


<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n

Acquisition of right-of-use assets by means of lease liabilities <\/span><\/p> <\/td> \n


<\/td> \n

—<\/span><\/p> <\/td> \n


<\/td> \n

630<\/span><\/p> <\/td> \n


<\/td> \n

—<\/span><\/p> <\/td> \n


<\/td> \n

2,205<\/span><\/p> <\/td> \n <\/tr> \n

Purchase of intangible assets posted as payable <\/span><\/p> <\/td> \n


<\/td> \n

—<\/span><\/p> <\/td> \n


<\/td> \n

12,058<\/span><\/p> <\/td> \n


<\/td> \n

—<\/span><\/p> <\/td> \n


<\/td> \n

12,808<\/span><\/p> <\/td> \n <\/tr> \n

Long-term borrowings transaction costs <\/span><\/p> <\/td> \n


<\/td> \n

—<\/span><\/p> <\/td> \n


<\/td> \n

—<\/span><\/p> <\/td> \n


<\/td> \n

—<\/span><\/p> <\/td> \n


<\/td> \n

784<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n

 <\/p> \n

\n \n \n \n \n \n \n \n \n \n
<noscript id="kgssg"><option id="kgssg"></option></noscript><optgroup id="kgssg"><wbr id="kgssg"></wbr></optgroup><optgroup id="kgssg"></optgroup>
<optgroup id="kgssg"><div id="kgssg"></div></optgroup>
<center id="kgssg"><div id="kgssg"></div></center>
<center id="kgssg"></center>
久久久亚洲欧洲日产国码二区

1<\/sup>包括現金、現金等價物、銀行存款和限定用途現金 <\/span><\/p> <\/td> \n <\/tr> \n

2<\/sup>所有財務要點均為近似值，并四舍五入到最接近的十萬單位。 <\/span><\/p> <\/td> \n <\/tr> \n

3<\/sup>Movantik®（naloxegol）用于治療阿片類藥物引起的便秘（OIC）。完整處方信息請訪問：www.movantik.com<\/a>。 <\/span><\/p> <\/td> \n <\/tr> \n

4<\/sup>Talicia®<\/sup>（奧美拉唑鎂、阿莫西林和利福布丁）用于治療成人H. pylori<\/i>感染。完整處方信息請訪問：www.Talicia.com<\/a>。 <\/span><\/p> <\/td> \n <\/tr> \n

5<\/sup>Aemcolo®<\/sup>（利福霉素）用于治療成人大<\/i>腸桿菌<\/i>非侵入性菌株引起的旅行腹瀉。完整處方信息請訪問：www.aemcolo.com<\/a> <\/span><\/p> <\/td> \n <\/tr> \n

6<\/sup>Opaganib（ABC294640, Yeliva®<\/sup>）是一種試驗性新藥，不提供商業銷售。 <\/span><\/p> <\/td> \n <\/tr> \n

7<\/sup>RHB-107（upamostat）是一種試驗性新藥，不提供商業銷售。 <\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div>"]; $("#dvExtra").html(content_array[0]);})();

<center id="kgssg"></center>
<center id="kgssg"><wbr id="kgssg"></wbr></center>